Nordhealth (OB:NORDH) Third Quarter 2024 Results
Key Financial Results
- Revenue: €11.2m (up 27% from 3Q 2023).
- Net loss: €807.0k (loss narrowed by 57% from 3Q 2023).
- €0.01 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nordhealth Earnings Insights
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Healthcare Services industry in Europe.
Performance of the market in Norway.
The company's shares are up 13% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Nordhealth you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Nordhealth might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OB:NORDH
Nordhealth
Provides healthcare software solutions in Norway, Finland, Sweden, Denmark, Germany, and internationally.
Flawless balance sheet with reasonable growth potential.
